Drugs

Jun 18, 2025, 09:15

Raul Cordoba: Nivolumab-AVD vs Brentuximab Vedotin–AVD in Advanced-Stage Classic Hodgkin Lymphoma

Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA), shared a post on X:

“Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 |⁩ Journal of Clinical Oncology”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivolumab-AVD Nivolumab-AVD

More posts featuring Raul Cordoba on OncoDaily

Alex F. Herrera Anamarija M. Perry Andrew M. Evens Brad Kahl Brentuximab Vedotin–AVD Brian T. Hess cancer Carla Casulo Hongli Li John P. Leonard Jonathan W. Friedberg Joo Y. Song Joseph M. Tuscano Joseph M. Unger Journal of Clinical Oncology Kelly Davison Michael LeBlanc Nancy L Bartlett Nivolumab-AVD OncoDaily Oncology Pallawi Torka Pankaj Kumar Raul Cordoba Ryan Jacobs Sairah Ahmed Sarah C. Rutherford Sharon M. Castellino Sonali M. Smith Susan K. Parsons

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma

Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025

Lisa A. Lacasse Welcomed Shane Jacobson as the New CEO of the ACS and the ACS CAN

ASCO and Community Oncology Alliance Have Released the Updated Oncology Medical Home Standards